Award
NIH Reporter #1R61NS138813-01A1
A novel gene therapy approach to reduce neurotoxicity in Parkinson's disease
Recipient
Van Andel Research Institute
Award Amount
$1,009,212.00
Ceiling
$1,009,212.00
Awarded
July 07, 2025
Identifier
1R61NS138813-01A1
NIH awarded $1,009,212 to Van Andel Research Institute for a gene therapy project targeting neurotoxicity in Parkinson's disease by modulating the kynurenine pathway enzyme ACMSD, aiming to reduce neurodegeneration and improve symptoms.
Description
This NIH R61/R33 phased project focuses on developing a gene therapy to modulate the enzyme ACMSD, reducing neurotoxic quinolinic acid levels and increasing protective picolinic acid to mitigate neurodegeneration in Parkinson's disease. The project includes vector testing, dose identification, and efficacy demonstration in animal models to support future clinical trials.